India, June 11 -- image credit- freepik

AstraZeneca Pharma India Ltd. (AZPIL), a global, science-led biopharmaceutical company, has announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilised powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer.

Breast cancer remains one of the most common cancers affecting women worldwide, and HER2-positive breast cancer is among its most aggressive forms.

In India, HER2-positive breast cancer, defined by HER2 gene amplification or protein overexpress...